secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2026-06-23T20:05:31+00:00
Accession:  0001193125-26-279428
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux Therapeutics CMO Dr. William Go departs; no impact on clinical timelines
------------------------------------------------------------------------------

- CMO William Go, M.D., Ph.D. departed June 23, 2026; company determined termination without Cause under severance plan.
- Company initiated search for successor; existing clinical leadership team assumes interim responsibilities.
- Departure not due to disagreement with company on operations, policies, or practices.
- Transition does not affect development strategy, regulatory plans, or previously disclosed clinical timelines.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000119312526279428/0001193125-26-279428-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000119312526279428/janx-20260623.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-279428

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer